NEWS AND DEVELOPMENT

  • Interim Phase IIb Data Show Promising Reduction In Risk of Recurrence and a Well-Tolerated Safety Profile in Patients with Resected, High-Risk Melanoma
    More
  • TLPLDC Demonstrates Encouraging Clinical Activity and Favorable Safety and Tolerability Profile in Combination with FDA-Approved Systemic Therapies
    More
  • Elios Therapeutics, LLC recently received FDA approval of its Investigational New Drug (IND) application and its randomized phase IIb trial planned to enroll 120 stage III and IV (resected) melanoma patients to assess the ability of a personalized vaccine to prevent recurrence.
    More
  • Vaccine for Cancer Comes Closer to Fruition as Immunotherapy Pioneer Joins Orbis Health Solutions
    More
  • Buddy Long, president of Perseus PCI, the advanced cancer treatment center headquartered in the Cayman Islands, has announced the appointment of Dr. Sook Yin MD as treating physician and clinic director at the company‚Äôs Cayman Islands clinic.
    More

Personalized Cancer Vaccine Moves to Phase IIb Trial at Leading U.S. Cancer Hospitals

AUSTIN, Texas, Dec. 23, 2014 /PRNewswire/ — Elios Therapeutics, LLC recently received FDA approval of its Investigational New Drug (IND) application and its randomized phase IIb trial planned to enroll 120 stage III and IV (resected) melanoma patients to assess the ability of a personalized vaccine to prevent recurrence. The trial will be conducted at a dozen leading academic cancer research hospitals in the United States.

“The Elios vaccine has shown effectiveness in metastatic patients, and delivered even more promising results in the adjuvant setting. Further, the vaccine has the safety profile to allow for treatment in a preventive setting,” explains George E. Peoples, MD, FACS and Chief Medical Officer, Elios Therapeutics, LLC. “Stage III and IV melanoma patients do not currently have an option for a safe, non-toxic, and effective adjuvant therapy. Melanoma at this stage recurs at an approximately 60-70 percent rate in two years, and once that happens, patients will very likely succumb to their disease. We believe that our vaccine technology can cut that rate significantly, preventing recurrence and death.”

Source: Yahoo.com